PRESS RELEASE: San Diego, CA (August 22, 2011) – Eidogen-Sertanty, Inc. has announced a new oncology knowledgebase focusing on emerging and hot targets. Complementing its flagship Kinase Knowledgebase (KKB), Eidogen-Sertanty's Oncology Knowledgebase (OKB) focuses on a broad spectrum of targets relevant to Colon cancer, Esophageal cancer, Glioma, Head and Neck cancer, Kidney cancer, Leukemia, Liver cancer, Lung cancer, Lymphoma, Melanoma, Ovarian cancer, Prostate cancer, Skin cancer, and Stomach cancer.

The OKB includes enzymatic and cell-based structure-activity data across Epigenetic targets, orphan nuclear receptors, and transcription factors, and includes data across several G protein-coupled receptors (GPCRs), Matrix Metalloproteinases (MMPs), Proteasomes, Farnesyltransferases, Aromatases, and8Phosphodiesterases.

Eidogen-Sertanty's Oncology Knowledgebase will be available for subscription in Q4 of 2011.

For more information, please contact:

Steve Muskal
760-651-2885
This e-mail address is being protected from spambots. You need JavaScript enabled to view it

About Eidogen-Sertanty, Inc.

Eidogen-Sertanty is a privately held company that is dedicated to helping scientists discover new medicines with innovative software technology and knowledgebases. To find out more about Eidogen-Sertanty please visit www.eidogen-sertanty.com.